Fingerprint
Dive into the research topics of 'Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial
Jessica Ailani, Richard B. Lipton, Susan Hutchinson, Kerry Knievel, Kaifeng Lu, Matthew Butler, Sung Yun Yu, Michelle Finnegan, Lawrence Severt, Joel M. Trugman
Research output: Contribution to journal › Article › peer-review
73
Scopus
citations